Premium
Agenus Inc (AGEN)
NASDAQ
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multip... Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others. Show more
AGEN LAWSUIT ALERT: The Gross Law Firm Notifies Agenus Inc. Investors of a Class Action Lawsuit and Upcoming Deadline PR Newswire NEW YORK, Sept. 26, 2024 NEW YORK, Sept. 26, 2024 /PRNewswire/...
AGEN LAWSUIT ALERT: The Gross Law Firm Notifies Agenus Inc. Investors of a Class Action Lawsuit and Upcoming Deadline PR Newswire NEW YORK, Sept. 23, 2024 NEW YORK, Sept. 23, 2024 /PRNewswire/...
Contact The Gross Law Firm by November 5, 2024 Deadline to Join Class Action Against Agenus Inc.(AGEN) PR Newswire NEW YORK, Sept. 19, 2024 NEW YORK, Sept. 19, 2024 /PRNewswire/ -- The Gross Law...
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Agenus Inc.(AGEN) Shareholders PR Newswire NEW YORK, Sept. 16, 2024 NEW YORK, Sept. 16, 2024 /PRNewswire/ -- The...
BOT/BAL Demonstrates Broad and Durable Activity in Advanced Sarcoma Population Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers...
AGEN INVESTOR ALERT: Edelson Lechtzin LLP Urges Agenus, Inc. (NASDAQ: AGEN) Shareholders to Seek Legal Counsel About the Pending Securities Fraud Class Action PR Newswire NEWTOWN, Pa., Sept. 11...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that updated data from the clinical trial of botensilimab and...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Agenus executives, Dr. Garo Armen, Chief...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.82 | -13.3550488599 | 6.14 | 6.38 | 4.94 | 555782 | 5.41560856 | CS |
| 4 | 0.29 | 5.76540755467 | 5.03 | 6.53 | 4.745 | 380666 | 5.50637292 | CS |
| 12 | -9.23 | -63.4364261168 | 14.55 | 18.74 | 4.41 | 697389 | 7.20095902 | CS |
| 26 | -5.48 | -50.7407407407 | 10.8 | 19.688 | 4.41 | 1605928 | 9.84432555 | CS |
| 52 | -17.68 | -76.8695652174 | 23 | 23.6 | 4.41 | 5670508 | 13.89602062 | CS |
| 156 | -112.88 | -95.4991539763 | 118.2 | 118.8 | 4.41 | 4978708 | 34.65749826 | CS |
| 260 | -48.28 | -90.0746268657 | 53.6 | 135.8 | 4.41 | 4126184 | 47.56134457 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
